MediaMedic

🌍 ⚕ Exclusive Interview: Revolutionizing APL Treatment with Professor Uwe Platzbecker We are excited to present an exclusive interview with Professor Uwe Platzbecker, conducted at the European Hematology Association (EHA) conference. In this insightful session, Professor Platzbecker shares the first results of the groundbreaking APOLLO trial, which aims to transform the treatment strategies for high-risk acute promyelocytic leukemia (APL). Join us as we explore the details of this landmark study and its implications for the future of APL treatment. Watch the full interview below to gain valuable insights into this transformative research. #Hematology #APL #EHA2024 #MedicalResearch #Oncology #HealthcareInnovation #HematologyFrontier

The European Hematology Association (European Hematology Association (EHA) congress has been a testament to the vibrant and dynamic nature of the hematology community. This year's event has been marked by an impressive array of education sessions, joint symposiums, and plenary sessions. The congress has served as a platform for the exchange of groundbreaking research findings and the fostering of collaborative efforts among hematologists worldwide. The atmosphere has been electric, with attendees eager to engage in discussions and share insights that will undoubtedly shape the future of hematology. #EHA2024 #HematologyCommunity #UtrechtEvent #ScientificSessions #Workshops #NetworkingOpportunities #GroundbreakingResearch #CollaborativeEfforts #HematologyFuture

🩺 BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors Traditional treatment for head and neck tumors mainly involves surgery, radiotherapy, and chemotherapy. Recently, immune checkpoint inhibitors have shown promising potential in treating head and neck squamous cell carcinoma, and new radiotherapy techniques such as proton and carbon ion therapy offer treatment options with reduced radiation toxicity. At the 2024 BOC/BOA conference, Professor Chaosu Hu from Fudan University Shanghai Cancer Center chaired the head and neck tumor session, sharing significant research findings from the 2024 ASCO conference. Oncology Frontier interviewed Professor Hu to explore the current diagnosis and treatment status and research progress in head and neck tumors. 🔬🌐 #BOC2024 #BOA2024 #HeadAndNeckCancer #Immunotherapy #ProtonTherapy #CarbonIonTherapy #OncologyResearch #CancerTreatment #MedicalInnovation #ClinicalAdvancements #HealthcareProgress

🧬 EHA International Perspective | Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study At EHA 2024, Professor Uwe Platzbecker presented key results from the APOLLO study, highlighting a new treatment strategy combining ATO and ATRA for high-risk APL patients. This study offers valuable insights into APL treatment and guides future research and clinical practices. 🔍🌐 #EHA2024 #APL #Leukemia #OncologyResearch #Hematology #APOLLOStudy #CancerTreatment #MedicalInnovation #ClinicalAdvancements #HealthcareProgress

🔍 BOC/BOA 2024丨New Breakthroughs in ADC Drugs for Breast Cancer Treatment—Professor Ying Fan Interprets the DB-06 and OptiTROP-Breast01 Studies In the field of breast cancer treatment, the rapid development of antibody-drug conjugates (ADCs) is gradually changing the traditional treatment landscape, bringing more hope to patients. The presentation of the DB-06 and OptiTROP-Breast01 studies at the 2024 ASCO conference has elevated the application of ADC drugs in breast cancer treatment to a new level. At the 2024 BOC/BOA conference, Oncology Frontier invited Professor Ying Fan from the Cancer Institute & Hospital, Chinese Academy of Medical Sciences, to provide an in-depth interpretation of these two research advances and discuss the latest developments in ADC drug treatment for HER2-low breast cancer and triple-negative breast cancer (TNBC). 🔬🌐 #BOC2024 #BOA2024 #BreastCancer #ADCTherapy #OncologyResearch #HER2Low #TNBC #CancerTreatment #MedicalInnovation #ClinicalAdvancements #Healthcar

At the EHA (European Hematology Association) congress , Professor Richard Van Wijk from the University Medical Center Utrecht delivered a captivating presentation titled "Activation of pyruvate kinase as a therapeutic option for rare hemolytic anemias." His insightful discussion on the potential of pyruvate kinase activation in treating these rare conditions has sparked significant interest among hematologists and researchers. The innovative approach presented by Professor Van Wijk could pave the way for new treatment strategies in the field of rare blood disorders. #EHACongress #Utrecht #UniversityMedicalCenterUtrecht #RichardVanWijk #HemolyticAnemias #PyruvateKinase #MedicalResearch #InnovativeTherapies #RareDiseases #Hematology

🧬 ASCO 2024 | Professor Xinan Sheng: First Immunotherapy Combined with ADC Neoadjuvant Treatment for MIBC Revealed, Meeting the Survival Needs of More Patients The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA, showcasing numerous cutting-edge research findings that will further advance the diagnosis and treatment practices in the field of urological tumors. Among them, a multicenter Phase II clinical study conducted in China, led by Peking University Cancer Hospital, on disitamab vedotin (RC48) combined with toripalimab for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) with HER2 expression has been included (Abstract No. 4568). "Oncology Frontier" invites Professor Xinan Sheng from Peking University Cancer Hospital to share the latest findings. 🔍🌐 #ASCO2024 #MIBC #Immunotherapy #ADCTherapy #BladderCancer #OncologyResearch #CancerTreatment #MedicalInnovation #ClinicalAdvancements #HealthcareProgress

Embrace the synergy of global expertise and local insights with Professor Zefei Jiang at the 2024 Best of American Society of Clinical Oncology (ASCO)/Best of CSCO. As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let's innovate together for a future where cancer treatment knows no borders. #BOC/BOA #GlobalHealth #CancerInnovation

At the EHA (European Hematology Association) congress, I witnessed the intellectual collision in the field of hematology. Scholars shared their research findings from the podium, with each presentation being a spark of knowledge and wisdom. Their profound insights into blood diseases have not only brought new enlightenment to the medical community but also hope to patients. #EHACongress #Hematology #MedicalConference #ScholarSpeeches #KnowledgeSpark #BloodDiseases #MedicalInsights #HopeForPatients #MemorableMoments

Goodbye Bangkok! 🌏 See You Next Year in Washington, D.C. at ISTH Conference 2025 #ISTH2024 #Bangkok #ISTH2025 #WashingtonDC #Thrombosis #Hemostasis